Aligos Therapeutics Aktie

At the Cantor Fitzgerald Healthcare Conference, Aligos Therapeutics unveiled an HBV strategy combining pevifoscorvir (a capsid-assembly modulator) for chronic suppression with the antisense oligonucleotide ALG‑170675 as a route toward functional cure. Pevifoscorvir showed high potency, good oral bioavailability and sustained S-antigen reduction in phase‑I data; a phase‑II superiority study versus tenofovir was expanded after an interim analysis did not meet the futility threshold. ALG‑170675 has entered clinical development in China and is intended to show additive to synergistic effects in combination with pevifoscorvir, substantially enlarging the addressable patient population. Further progress depends on ongoing clinical data and regulatory steps. » Altro su de.investing.com

Aligos Therapeutics shares climbed 7.6% in premarket trading to $6.55, despite no company-specific news that day. The move was driven by continued positive sentiment following strong Q2 results showing a significantly smaller net loss and an EPS beat, and by non-dilutive funding from a licensing agreement for Pevifoscorvir sodium in China. In addition, full patient recruitment for the Phase-2 B-SUPREME study was completed, reducing pipeline risk. The outperformance came despite weaker U.S. indices, and the stock remains well below its 52-week high of $13.69. » Altro su de.investing.com

Aligos has completed recruitment for both parts of the phase‑2 B‑SUPREME study of pevifoscorvir sodium in chronic hepatitis B (131 HBeAg‑positive in part 1a, 114 HBeAg‑negative in part 2a). The larger participant number in part 1a made a second interim sample‑size analysis unnecessary. The stock rose 13% on the news last week but is down 29% year‑to‑date; the company has a market capitalization of USD 41 million and more cash than debt. Key safety and efficacy data are expected in late Q3 2027. » Altro su de.investing.com